Most Read

Bristol Myers Squibb has been granted approval by the European Commission (EC) for the use of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) to treat adults with advanced

Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.

Gilead Sciences has announced the accelerated approval of Trodelvy (or sacituzumab govitecan-hziy) by the US Food and Drug Administration (FDA) in the treatment of locally advanced or metastatic

Integrated pharmaceutical company Dr. Reddy’s Laboratories has secured Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) to import Russia’s Sputnik V vaccine into India.

AT-100 is a new recombinant human protein rhSP-D and is an engineered version of an endogenous protein that reduces inflammation and infection while modulating the immune response to

Global biopharmaceutical company Sanofi has acquired privately owned, pre-clinical stage biotech company Tidal Therapeutics, which brings with it an mRNA-based approach for in vivo (inside the body) reprogramming

Biogen and Bio-Thera Solutions have entered into a commercialisation and license agreement for the development, manufacturing and commercialisation of BAT1806. The terms of the agreement stipulate that Biogen makes

AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines

The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly and Incyte’s supplemental New Drug Application (sNDA) for OLUMIANT (baricitinib). The new drug